Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-26 @ 12:19 PM
Ignite Modification Date:
2025-12-26 @ 12:19 PM
NCT ID:
NCT00911300
Group ID:
EG000
Title:
Fondaparinux
Description:
For CN par., 7.5 mg fondaparinux was injected OD subcutaneously (for par. with BW 50-100 kg; for par. with BW \>100 kg, 10 mg fondaparinux was administered using a disposable prefilled syringe for the first 7-10 days after randomization, followed by 3 weeks of 2.5 mg fondaparinux OD (until Day 28+/-4). For CP par. with CrCl \>= 50 mL/min, 7.5 mg fondaparinux was injected OD (for par. with BW 50-100 kg); for par. with BW \>100 kg, 10 mg fondaparinux was administered OD. For CP par. with CrCl 30 to \<50 mL/min, 5 mg fondaparinux was injected OD (for par. with BW 50-100 kg); for par. with BW \>100 kg, 7.5 mg fondaparinux was injected for 28+/-4 days. If the second TEE showed thrombus disappearance, treatment continued until 7-10 days after the second TEE followed by 3 weeks of 2.5 mg fondaparinux OD (total treatment duration: 56+/-4 days).
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
30
Serious Number At Risk:
174
Other Number Affected:
68
Other Number At Risk:
174
Study:
NCT00911300
Results Section:
NCT00911300
Adverse Events Module:
NCT00911300